Use of Dermatan Sulfrates and/or Desulfated Heparins to Treat or Prevent Heparinoid-Induced Autoimmune Responses
    10.
    发明申请
    Use of Dermatan Sulfrates and/or Desulfated Heparins to Treat or Prevent Heparinoid-Induced Autoimmune Responses 有权
    使用皮肤硫酸盐和/或脱硫肝素来治疗或预防肝素诱导的自身免疫反应

    公开(公告)号:US20080138380A1

    公开(公告)日:2008-06-12

    申请号:US12014948

    申请日:2008-01-16

    申请人: Alan D. Cardin

    发明人: Alan D. Cardin

    摘要: Dermatan sulfates and/or O-desulfated heparins useful in treating and preventing heparinoid-induced autoimmune responses, in particular heparin-induced thrombocytopenia (HIT) and its associated disease states. The dermatan sulfates comprise repeating disulfated and/or trisulfated disaccharide units of L-iduronic acid and N-acetyl-D-galactosamine. The O-desulfated heparins comprise heparin molecules selectively O-desulfated at the 2-O and/or 3-O positions of the uronic acid and glucosamine saccharide residues. Particularly effective dermatan sulfate HIT antagonists have a mean molecular weight of from about 2000 to about 10,000 Daltons.

    摘要翻译: 可用于治疗和预防类肝素诱导的自身免疫应答,特别是肝素诱导的血小板减少症(HIT)及其相关疾病状态的皮肤硫酸盐和/或O-脱硫乙酰肝素。 皮肤硫酸盐包含L-艾可糖醛酸和N-乙酰基-D-半乳糖胺的重复的二硫酸化和/或三硫酸化二糖单元。 O-脱硫肝素包括在糖醛酸和葡糖胺糖残基的2-O和/或3-O位选择性地脱硫的肝素分子。 特别有效的硫酸皮肤素HIT拮抗剂的平均分子量为约2000至约10,000道尔顿。